Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.66 |
| ▸ | SIK2 | Q9H0K1 | 13/20 | 0.54 |
| ▸ | SIK3 | Q9Y2K2 | 13/20 | 0.54 |
| ▸ | ABL1 | P00519 | 12/20 | 0.54 |
| ▸ | SIK1 | P57059 | 11/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257532 | 0.88 | SIK2 (0.67) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL19436378 | 0.87 | ABL1 (0.66) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL4252892 | 0.85 | ABL1 (0.69) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL3536666 | 0.84 | ABL1 (0.75) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL30144989 | 0.84 | ABL1 (0.75) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL14665835 | 0.84 | ABL1 (0.64) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL19436374 | 0.81 | LCK (0.53) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL19436379 | 0.81 | ABL1 (0.51) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL19436380 | 0.81 | SIK2 (0.51) | LCKSIK2SIK3ABL1SIK1 | |
| SCHEMBL773125 | 0.80 | LCK (1.00) | LCKSIK2SIK3ABL1SIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LCK 56/4885SIK2 832/4885SIK3 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.